2.26
2.26 (-0.85%)
As of Mar 06, 2024
Equillium, Inc. [EQ]
Source:
Company Overview
We are a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking, which drives a number of immuno-inflammatory diseases across multiple therapeutic areas. Therefore, we believe itolizumab (EQ001) may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.
Country | United States |
Headquarters | la jolla, california |
Phone Number | (858) 412-5302 |
Industry | manufacturing |
CEO | Bruce D. Steel |
Website | equilliumbio.com |